Radiopharm and Starpharma Collaborate on Novel Cancer Therapy

Starpharma Holdings Limited ( (AU:SPL) ) has issued an announcement.

Radiopharm Theranostics has entered into a research and option agreement with Starpharma to develop a novel radiopharmaceutical molecule using Starpharma’s DEP® platform. This collaboration marks a significant milestone for both companies, potentially enhancing Radiopharm’s cancer treatment offerings and demonstrating the applicability of Starpharma’s technology in targeted cancer therapies. The agreement includes an exclusive option for Radiopharm to license the developed asset, with significant financial terms tied to successful development and commercialization.

More about Starpharma Holdings Limited

Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which is used to improve health outcomes for patients with serious illnesses like cancer. Their portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, and over-the-counter products. Radiopharm Theranostics is a clinical-stage company developing radiopharmaceutical products for cancer diagnostics and therapeutics, with a focus on areas of high unmet medical need.

Average Trading Volume: 805,090

Technical Sentiment Signal: Hold

Current Market Cap: A$92.01M

See more insights into SPL stock on TipRanks’ Stock Analysis page.